Background Familial Mediterranean fever (FMF) has episodic or subclinical inflammation that may lead to a decrease in bone mineral density (BMD).
Objective To assess BMD in Egyptian children with FMF on genetic basis.
Subjects and methods A cross sectional study included 45 FMF patients and 25 control children of both sexes, with age range between 3–16 years old. The patients were reclassified into 2 groups: Group I (A) 23 cases used colchicines for 1 month or less, and Group I (B) 22 cases used colchicines for more than 6 months. For both patients and control, MEFV mutations were defined using molecular genetics technique and BMD was measured by DXA at 2 sites: proximal femur and the lumber spines.
Results four frequent gene mutation where found in the patient group: E148Q (35.6%), V726A (33.3%), M680I (28.9.0%) and M694V (2.2%). There were also 4 heterozygous gene mutations in 40% of control children. Patients received Colchicines treatment for less than 1 month had highly significant lower values of BMD at femur and lumber spines than control children (p < 0.007, p < 0.001). Patients received Colchicines treatment for more than 6 months had improved values of BMD at femur compared to control, but there were still significant differences between them at lumbar spine (p > 0.036). There are insignificant effect of type of gene mutation on BMD and the risk of osteopenia among the patients.
Conclusion FMF had significant effect on BMD. However; regular use of colchicines treatment improves this effect mainly at femur.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.